Bcr-Abl is found in more than 95% of cases with CML. The mechanism of Bcr-Abl-induced transformation is not fully understood. Bcr-Abl is a constitutively active tyrosine kinase with transforming ...

IL-3 protects p210 Bcr-Abl-transformed 32D and Baf3 cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors During our preliminary studies with PD180970, we found that the viability of ...

As the disease progresses, it’s important to regularly adapt treatment strategies based on consistent monitoring of BCR-ABL levels. This allows doctors to track the disease’s progression and ...

普纳替尼获批的适应症较为广泛，主要用于以下几类白血病的治疗：一是既往用药耐药或不耐受的慢性髓性白血病（CML）；二是复发或难治性费城染色体阳性（Ph+）急性淋巴细胞白血病（ALL）；三是 T315I 阳性慢性髓性白血病（CML）或 T315I 阳性费城染色体阳性（Ph+）急性淋巴细胞白血病（ALL） 。从全国一体化在线政务服务平台以及国家药品监督管理局政务服务门户公布的 2024 年 09 月 ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

ABL 在医学上通常指的是一种基因，即 Abelson 基因，它与某些血液系统疾病密切相关，比如慢性粒细胞白血病。此外，ABL 也可能指某种检测指标、特定的实验室技术，或者特定的药物靶点等。 1. ABL 基因：Abelson 基因在慢性粒细胞白血病的发生发展中起到重要作用。当这个基因发生异常融合，如与 BCR 基因融合形成 BCR-ABL ...

The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 ...

为解决慢性髓性白血病（CML）对 BCR-ABLi 耐药难题，俄罗斯科学院基因生物学研究所研究人员开展 CDK8/19 抑制对 CML 细胞影响的研究。发现 CDK8/19i 可增敏 BCR-ABLi，加速癌细胞死亡。极具科研价值，推荐一读！ 俄罗斯科学院基因生物学研究所（Institute of Gene Biology, Russian Academy of Sciences）的研究人员 Al ...